CU23791A3 - Método para la producción de proteínas y anticuerpos mejorados - Google Patents

Método para la producción de proteínas y anticuerpos mejorados

Info

Publication number
CU23791A3
CU23791A3 CU20090033A CU20090033A CU23791A3 CU 23791 A3 CU23791 A3 CU 23791A3 CU 20090033 A CU20090033 A CU 20090033A CU 20090033 A CU20090033 A CU 20090033A CU 23791 A3 CU23791 A3 CU 23791A3
Authority
CU
Cuba
Prior art keywords
production
antibodies
molecule composition
protein molecule
improved proteins
Prior art date
Application number
CU20090033A
Other languages
English (en)
Inventor
Hans Baumeister
Lars Stoeckl
Renate Stahn
Antje Danielczyk
Steffen Goletz
Anja Loeffler
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39157600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23791(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06090171A external-priority patent/EP1900750A1/en
Priority claimed from EP06090190A external-priority patent/EP1911766A1/en
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of CU23791A3 publication Critical patent/CU23791A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1735—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La solicitud se relaciona con método para producir una composición de molécula de proteína que tiene un patrón de glicosilación definida que comprende: a) introducir en una célula anfitriona la cual es una célula sanguínea humana inmortalizada, al menos un ácido nucleico que codifica para al menos parte de la proteína; y b) cultivar la célula anfitriona bajo condiciones que permiten la producción de la composición de moléculas de proteína; y c) aislar la composición de molécula de proteína.
CU20090033A 2006-09-10 2009-03-10 Método para la producción de proteínas y anticuerpos mejorados CU23791A3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06090162 2006-09-10
EP06090171A EP1900750A1 (en) 2006-09-18 2006-09-18 Fully human high yield production system for improved antibodies
EP06090190A EP1911766A1 (en) 2006-10-13 2006-10-13 Use of human cells of myeloid leukaemia origin for expression of antibodies
EP07090094 2007-05-04

Publications (1)

Publication Number Publication Date
CU23791A3 true CU23791A3 (es) 2012-03-15

Family

ID=39157600

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20090033A CU23791A3 (es) 2006-09-10 2009-03-10 Método para la producción de proteínas y anticuerpos mejorados

Country Status (25)

Country Link
US (3) US9051356B2 (es)
EP (5) EP2428225A3 (es)
JP (3) JP5767779B2 (es)
KR (3) KR20150126730A (es)
CN (1) CN103436574B (es)
AU (1) AU2007294122B2 (es)
BR (1) BRPI0716997B8 (es)
CA (1) CA2662226C (es)
CU (1) CU23791A3 (es)
CY (1) CY1116279T1 (es)
DK (2) DK2073842T4 (es)
EA (1) EA017622B1 (es)
ES (2) ES2533964T5 (es)
FI (1) FI2073842T4 (es)
HR (1) HRP20150307T1 (es)
IL (1) IL197459A (es)
MX (1) MX2009002388A (es)
NZ (1) NZ575974A (es)
PL (1) PL2073842T5 (es)
PT (1) PT2073842E (es)
RS (1) RS53861B1 (es)
SG (1) SG174792A1 (es)
SI (1) SI2073842T1 (es)
WO (1) WO2008028686A2 (es)
ZA (1) ZA201001903B (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3528611B2 (ja) * 1998-07-16 2004-05-17 Ｊｆｅスチール株式会社 結束材の切断方法及びその装置
EP2428225A3 (en) 2006-09-10 2012-05-09 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
WO2008135259A2 (en) * 2007-05-04 2008-11-13 Glycotope Gmbh Antibody molecule composition
GB0812277D0 (en) * 2008-07-04 2008-08-13 Fusion Antibodies Ltd Antibody and uses thereof
CN102292640B (zh) 2009-01-22 2014-07-02 动量制药公司 在来源于CHO细胞的糖蛋白产物中的含有半乳糖-α-1,3-半乳糖的N-聚糖
US20120100576A1 (en) 2009-07-08 2012-04-26 Glycotope Gmbh Perfusion bioreactor
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
WO2012020059A1 (en) 2010-08-10 2012-02-16 Glycotope Gmbh Humanized egfr antibodies
BR112013003095B1 (pt) * 2010-08-10 2023-03-28 Glycotope Gmbh Método para controle da meia-vida em circulação de um anticorpo ou um fragmento ou derivado funcional do mesmo, composições de anticorpo, seu usos e seus métodos de produção
US9051370B2 (en) 2010-08-10 2015-06-09 Glycotope Gmbh Humanized EGFR antibodies
PL2655600T3 (pl) 2010-12-21 2017-08-31 Glycotope Gmbh Sposób hodowania ludzkich komórek białaczek szpikowych i komórek od nich pochodzących
AU2012244673A1 (en) 2011-04-21 2013-11-28 Seattle Genetics, Inc. Novel binder-drug conjugates (ADCs) and their use
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR20140101331A (ko) * 2011-08-10 2014-08-19 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 고도로 갈락토실화된 항체
BR112014004065A2 (pt) 2011-08-22 2017-03-14 Glycotope Gmbh micro-organismos carregando um antígeno de tumor
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
EA201590237A1 (ru) 2012-07-18 2015-05-29 Гликотоп Гмбх Новые способы лечения антителами против her2 с низкой степенью фукозилирования
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
JP2016504047A (ja) 2013-01-18 2016-02-12 グリコトープ ゲーエムベーハー タンパク質発現を向上させるための融合ペプチド
CN105308068A (zh) 2013-02-13 2016-02-03 法国化学与生物科技实验室 高度半乳糖基化的抗TNF-α抗体及其用途
US20160002330A1 (en) * 2013-02-13 2016-01-07 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Cetuximab with modified glycosylation and uses thereof
BR112015019348A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
CA2900912A1 (en) * 2013-02-13 2014-08-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-her2 antibodies and uses thereof
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
MX2015012824A (es) 2013-03-14 2016-06-24 Abbott Lab Antigenos recombinantes ns3 del vhc y mutantes de los mismos para la deteccion mejorada de anticuerpos.
BR112015023239A8 (pt) 2013-03-14 2018-04-17 Abbott Lab ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
MX376492B (es) 2013-03-14 2025-03-07 Abbott Lab Anticuerpos monoclonares que se unen al dominio de unión a lípidos de la proteína de la cápside del virus de la hepatitis c (vhc)
ES2834113T3 (es) * 2013-03-15 2021-06-16 H Lundbeck As Purificación de anticuerpos y monitorización de la pureza
EA201591977A1 (ru) 2013-04-22 2016-06-30 Гликотоп Гмбх Противораковая терапия анти-egfr антителами, имеющими низкое фукозилирование
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) * 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN106163568B (zh) 2013-12-23 2021-03-23 拜耳制药股份公司 含纺锤体驱动蛋白（ksp）的抗体药物偶联物（adc）
BR112016019893B1 (pt) * 2014-03-05 2023-02-14 Ultragenyx Pharmaceutical Inc Composição
US20150307546A1 (en) * 2014-04-29 2015-10-29 Georgia Tech Research Corporation Thermo-responsive lectin-elp fusion binding ligands for glycoprotein purification by affinity precipitation
CN105820248A (zh) * 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型抗egfr单克隆抗体的制备方法及应用
LU92659B1 (en) * 2015-02-23 2016-08-24 Glycotope Gmbh Glycooptimized antibody drug conjugates
RU2716974C2 (ru) 2015-03-31 2020-03-17 Гликотоп Гмбх Эукариотические экспрессионные векторы, содержащие регуляторные элементы кластеров гена глобина
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
AR104956A1 (es) 2015-06-09 2017-08-30 Glycotope Gmbh MÉTODO MEJORADO PARA LA PRODUCCIÓN DE POLIPÉPTIDOS g-CARBOXILADOS
EP3310440A1 (de) 2015-06-22 2018-04-25 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen
HK1246717A1 (zh) 2015-06-23 2018-09-14 Bayer Pharma Aktiengesellschaft Ksp抑制剂的靶向缀合物
WO2016207328A1 (en) 2015-06-24 2016-12-29 Glycotope Gmbh PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP4548979A3 (en) * 2015-09-11 2025-07-23 Nascent Biotech, Inc. Enhanced delivery of drugs to the brain
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
US20170114127A1 (en) 2015-10-22 2017-04-27 Massachusetts Institute Of Technology Vegf-a-binding proteins and her2-binding proteins with enhanced stability against aggregation
WO2017162733A1 (en) * 2016-03-22 2017-09-28 Glycotope Gmbh Iga antibodies with enhanced stability
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
JP7022707B2 (ja) 2016-06-15 2022-02-18 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤および抗ｃｄ１２３抗体を含む特異的抗体－薬物－コンジュゲート（ａｄｃ）
US11713458B2 (en) 2016-06-20 2023-08-01 Octapharma Ag Means and methods for modifying multiple alleles
FR3060395B1 (fr) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-her2
FR3060394B1 (fr) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-amhrii
EP3558387B1 (de) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
PE20191235A1 (es) 2016-12-21 2019-09-11 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente
US12059472B2 (en) 2016-12-21 2024-08-13 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
WO2018138113A1 (en) 2017-01-27 2018-08-02 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
JP6829357B2 (ja) * 2017-03-17 2021-02-10 住友ベークライト株式会社 抗体の糖鎖検出法
CA3057758A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh Pd-l1 and ta-muc1 antibodies
US20200087410A1 (en) 2017-03-29 2020-03-19 Glycotope Gmbh Humanized anti-cd40 antibodies
KR20190134994A (ko) 2017-03-29 2019-12-05 글리코토페 게엠베하 Muc1 및 cd3에 결합하는 다중특이적 항체 작제물
AU2018328113B2 (en) 2017-09-06 2023-09-07 Airway Therapeutics, Inc. Methods, compositions and cells for preparing surfactant protein D (SP-D)
AU2018328112B2 (en) * 2017-09-06 2023-08-24 Airway Therapeutics, Inc. Methods and compositions for preparing surfactant protein D (SP-D)
BR112020015202A2 (pt) 2018-03-01 2020-12-29 Glycotope Gmbh Construções de proteínas de fusão compreendendo um anticorpo anti-muc1 e il-15
HUE067382T2 (hu) 2018-05-18 2024-10-28 Daiichi Sankyo Co Ltd Anti-MUC1-exatecan antitest-hatóanyag konjugátum
US12168690B2 (en) * 2019-07-26 2024-12-17 Abl Bio Inc. Anti-EGFR/anti-4-1BB bispecific antibody
EP3931303A1 (en) 2019-12-06 2022-01-05 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
KR20230030626A (ko) 2020-06-30 2023-03-06 글리코토페 게엠베하 루이스 y에 대한 인간화된 항체
KR20250021299A (ko) 2022-03-16 2025-02-12 펜틱사팜 아게 Lypd3에 대한 항체
WO2025099324A1 (en) 2023-11-10 2025-05-15 Tixapharm Ag Antibodies against cd44
WO2025132836A1 (en) 2023-12-19 2025-06-26 Pentixapharm Ag Antibodies against cd24

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
AU2353384A (en) * 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4931275A (en) * 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
US5683674A (en) * 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
DK0573551T3 (da) 1991-02-27 2003-08-04 Micromet Ag Serinrige peptidlinkere
DE69329643T2 (de) * 1992-04-13 2001-03-01 Dana-Farber Cancer Institute, Inc. Gegen karzinom-assoziierte antigene gerichtete antikörper
US5804187A (en) * 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
DE69434447T2 (de) 1993-06-07 2006-05-18 Vical, Inc., San Diego Für die gentherapie verwendbare plasmide
DE4329004A1 (de) 1993-08-28 1995-03-09 Max Delbrueck Centrum Monoklonale Antikörper gegen das Thomsen-Friedenreich-Antigen, ihre Herstellung und ihre Verwendung zum Tumornachweis
WO1995010538A1 (en) * 1993-10-15 1995-04-20 The University Of North Carolina At Chapel Hill Dna encoding the human p2u receptor and null cells expressing p2u receptors
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5888773A (en) * 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
JPH11509088A (ja) 1995-06-23 1999-08-17 プレジデント アンド フェローズ オブ ハーバード カレッジ 血管内皮増殖因子受容体をコードする遺伝子の転写調節
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1997040182A1 (de) 1996-04-19 1997-10-30 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
EP1987845B1 (en) * 1997-11-20 2012-03-21 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor.
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
AUPP816899A0 (en) 1999-01-14 1999-02-11 Food Technology Innovations Pty Limited Improved microbial products
AU3508300A (en) 1999-03-02 2000-09-21 Human Genome Sciences, Inc. Engineering intracellular sialylation pathways
DK1167537T3 (da) * 1999-03-30 2008-11-10 Japan Tobacco Inc Fremgangsmåde til fremstilling af et monoklonalt antistof
JP4488579B2 (ja) * 1999-03-30 2010-06-23 日本たばこ産業株式会社 モノクローナル抗体の製造方法
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
ES2239032T3 (es) 1999-08-18 2005-09-16 Altarex Medical Corp. Anticuerpo terapeutico contra el antigeno muc-1 y metodos para su uso.
US7147850B2 (en) * 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
WO2001023421A2 (en) * 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
FR2809312B1 (fr) 2000-05-25 2002-07-12 Gervais Danone Sa Utilisation de l. casei dans des compositions immunostimulantes
CA2424977C (en) * 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
ES2362413T3 (es) 2001-02-01 2011-07-05 Kabushiki Kaisha Yakult Honsha Procedimiento de evaluación del grado de acceso al intestino de bifidobacterium en alimento o bebida de leche fermentada.
DE10139428A1 (de) 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
EP1419176A2 (en) * 2001-08-17 2004-05-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Glycoconjugates of sialic acid derivates, methods for their production and use thereof
JP2005515974A (ja) * 2001-10-22 2005-06-02 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 卵胞形成のためのゴナドドロピン
GB0125473D0 (en) 2001-10-24 2001-12-12 Syngenta Ltd Chemical process
EP1451217A4 (en) 2001-11-20 2005-10-12 Atgen Co Ltd NEW PEPTIDES PROVIDING ENVIRONMENTAL RESISTANCE, AND FUSION PROTEINS CONTAINING THOSE PEPTIDES
AU2003266236A1 (en) * 2002-07-22 2004-02-09 Nemod Immuntherapie Ag Method for the production of an immunostimulating mucin (muc1)
ES2353753T3 (es) * 2002-08-16 2011-03-04 Glycotope Gmbh Procedimiento para la producción de lisados de células tumorales inducidas por temperatura para usar como compuestos inmunógenos.
DE10256900A1 (de) * 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
SI1654353T1 (sl) 2003-08-18 2013-09-30 Glycotope Gmbh Tumorski celični liniji NM-F9 (DSM ACC2606) in NM-D4 (DSM ACC2605), njihove uporabe
FR2861080B1 (fr) * 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
US8609370B2 (en) * 2004-02-13 2013-12-17 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
WO2005108423A1 (en) 2004-05-11 2005-11-17 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
US7374755B2 (en) 2004-07-26 2008-05-20 The Research Foundation Of State University Of New York Therapeutic use of anti-TF-Antigen antibody
EP1987518A1 (en) * 2006-02-14 2008-11-05 Koninklijke Philips Electronics N.V. Bit detection for optical disc reading
WO2007124992A1 (en) 2006-04-28 2007-11-08 Unilever N.V. Method of manufacturing a cultured edible product comprising omega-3 polyunsaturated fatty acids
EP1900750A1 (en) 2006-09-18 2008-03-19 Glycotope Gmbh Fully human high yield production system for improved antibodies
EP2428225A3 (en) 2006-09-10 2012-05-09 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
EP1911766A1 (en) 2006-10-13 2008-04-16 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl) * 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
AU2009248410B2 (en) 2008-05-13 2014-07-24 Glycotope Gmbh Fermentation process
US9079957B2 (en) 2009-04-16 2015-07-14 The University Of Tokyo Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
JP2016504047A (ja) 2013-01-18 2016-02-12 グリコトープ ゲーエムベーハー タンパク質発現を向上させるための融合ペプチド
JP2015138634A (ja) 2014-01-22 2015-07-30 株式会社オートネットワーク技術研究所 端子金具付き電線及びその製造方法

Also Published As

Publication number Publication date
JP2015146819A (ja) 2015-08-20
EP2073842B2 (en) 2023-10-18
MX2009002388A (es) 2009-06-02
EP2428224A3 (en) 2012-05-09
PT2073842E (pt) 2015-04-07
PL2073842T5 (pl) 2024-12-02
KR20150126730A (ko) 2015-11-12
DK2428224T3 (en) 2017-03-27
EP2428225A2 (en) 2012-03-14
US20150368363A1 (en) 2015-12-24
CA2662226C (en) 2020-08-04
BRPI0716997A8 (pt) 2019-02-05
HRP20150307T1 (hr) 2015-04-24
SG174792A1 (en) 2011-10-28
KR20090077911A (ko) 2009-07-16
BRPI0716997B8 (pt) 2021-05-25
EA017622B1 (ru) 2013-01-30
KR20170021375A (ko) 2017-02-27
NZ575974A (en) 2012-03-30
BRPI0716997A2 (pt) 2013-10-15
CA2662226A1 (en) 2008-03-13
US10280230B2 (en) 2019-05-07
EP2073842B1 (en) 2014-12-31
EP2428224A2 (en) 2012-03-14
CY1116279T1 (el) 2017-02-08
EP2073842A2 (en) 2009-07-01
DK2073842T3 (da) 2015-04-13
EA200970263A1 (ru) 2009-08-28
EP2428223A2 (en) 2012-03-14
US20190359731A1 (en) 2019-11-28
DK2073842T4 (da) 2024-01-15
JP5767779B2 (ja) 2015-08-19
ES2533964T3 (es) 2015-04-16
IL197459A0 (en) 2011-08-01
US20100028947A1 (en) 2010-02-04
SI2073842T1 (sl) 2015-05-29
CN103436574A (zh) 2013-12-11
WO2008028686A2 (en) 2008-03-13
WO2008028686A3 (en) 2008-06-12
JP2017123879A (ja) 2017-07-20
ES2533964T5 (es) 2024-05-09
ES2620261T3 (es) 2017-06-28
ZA201001903B (en) 2010-11-24
EP2428225A3 (en) 2012-05-09
US9051356B2 (en) 2015-06-09
EP2428224B1 (en) 2016-12-21
JP6166303B2 (ja) 2017-07-19
RS53861B1 (sr) 2015-08-31
KR101603632B1 (ko) 2016-03-16
AU2007294122A1 (en) 2008-03-13
EP2428223A3 (en) 2012-05-16
JP2010502204A (ja) 2010-01-28
EP3539981A1 (en) 2019-09-18
IL197459A (en) 2015-08-31
CN103436574B (zh) 2016-08-10
AU2007294122B2 (en) 2013-03-07
BRPI0716997B1 (pt) 2020-06-02
PL2073842T3 (pl) 2015-06-30
FI2073842T4 (fi) 2024-01-15

Similar Documents

Publication Publication Date Title
CU23791A3 (es) Método para la producción de proteínas y anticuerpos mejorados
BRPI0620803B8 (pt) anticorpo isolado ou fragmento de anticorpo anti-her-3, seu processo de preparação, composição farmacêutica e kit compreendendo o mesmo, molécula de ácido nucléico codificando o referido anticorpo, vetor compreendendo o mesmo, microrganismo transgênico, bem como método para diagnosticar uma doença associada a her-3
ATE517192T1 (de) Verfahren zur isolierung von zellen
CY1110860T1 (el) Αναστροφη μεταγραφαση τελομερασης πτηνου
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
GB201003701D0 (en) System for the expression of a protein
IN2012DN00834A (es)
CR9969A (es) Anticuerpos anti-globulomero ab, porciones de union a antigeno de estos, hibridomas correspondientes, acidos nucleicos, vectores, celulas huesped, metodos para producir dichos anticuerpos, composiciones que comprenden dichos anticuerpos
CL2010001425A1 (es) Proteina de union que comprende una cadena polipeptidica capaz de unir un par de antigenos; acido nucleico aislado que codifica dicha proteina de union; vector y celula huesped; metodo para producir proteina de union; composicion farmaceutica que comprende dicha proteina.
NI200900027A (es) Anticuerpos monoclonales humanos específicos para light humanos antagonistas.
WO2008005847A3 (en) Method of producing factor viii proteins by recombinant methods
BR112012013330A2 (pt) composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
BRPI0516572A (pt) métodos e composições para melhorar a produção de proteìnas recombinantes
BR112012007821A2 (pt) polipeptídeos para ligação ao "receptor de produtos finais de glicação avançada" bem como composições e métodos envolvendo os mesmos
UA101142C2 (ru) Способ разработки антитела
ATE469917T2 (de) Verfahren zur gewinnung von antikörpern
DE502006006865D1 (de) Neue dehydrogenasen, deren derivate und ein verfahren zur herstellung von optisch aktiven alkanolen
EA200700233A1 (ru) Новая последовательность для повышения экспрессии нуклеиновой кислоты
MX2024008738A (es) Metodos de desglicosilacion para electroforesis de proteinas glicosiladas.
WO2009090269A3 (en) Markers and diagnostic methods for metastasis
ATE445009T1 (de) Signalpeptid zur herstellung eines polypeptids
WO2008002548A3 (en) Novel human acidic mammalian chitinase and use thereof
ECSP099192A (es) Anticuerpos monoclonales humanos específicos para light humano antagonistas
WO2013042917A3 (ko) 중공사막을 이용한 단백질의 효소 처리장치 및 이를 이용한 온-라인 프로테오믹스 방법

Legal Events

Date Code Title Description
FG Grant of patent